NCT06233942 2026-03-18
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
102 trialsNCT06427941 2026-03-18
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06625775 2026-03-18
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT06131840 2026-03-13
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
Phase 1 Recruiting
NCT06663319 2026-03-13
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06704724 2026-03-13
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Active not recruiting
NCT07470853 2026-03-13
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Whitehawk Therapeutics, Inc.
Phase 1 Recruiting
NCT04929223 2026-03-03
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT06447662 2026-02-25
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting
NCT05647122 2026-02-20
EGRET
AstraZeneca
Phase 1 Recruiting
NCT06265688 2026-02-20
First In Human Study of CX-2051 in Advanced Solid Tumors
CytomX Therapeutics
Phase 1 Recruiting
NCT04449874 2026-02-12
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Genentech, Inc.
Phase 1 Active not recruiting
NCT05238922 2026-02-10
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06469281 2026-02-03
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT03798626 2026-01-27
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT07278336 2026-01-20
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
AbbVie
Phase 1 Recruiting
NCT06400472 2026-01-14
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT07277270 2026-01-07
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Recruiting
NCT07318805 2026-01-06
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
Phase 1 Recruiting
NCT05836324 2025-12-18
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06478693 2025-12-18
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Myeloid Therapeutics
Phase 1 Recruiting
NCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
NCT05029882 2025-10-29
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie
Phase 1 Active not recruiting
NCT05005403 2025-10-28
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
AbbVie
Phase 1 Recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT06769425 2025-06-24
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05848739 2025-05-11
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Sapience Therapeutics
Phase 1 Recruiting
NCT04925284 2025-04-04
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
Phase 1 Completed
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT05828459 2025-03-20
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Onward Therapeutics
Phase 1 Recruiting
NCT05087992 2025-02-19
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
Boehringer Ingelheim
Phase 1 Completed
NCT06825624 2025-02-13
ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT06232902 2024-12-18
A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers
Qilu Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT04516447 2024-11-26
A Study of ZN-c3 in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Recruiting
NCT05824559 2024-11-21
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
MEI Pharma, Inc.
Phase 1 Terminated
NCT06448364 2024-11-06
LTbR
Pfizer
Phase 1 Terminated
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06540261 2024-09-19
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT01916447 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
Taiho Oncology, Inc.
Phase 1 Completed
NCT05022927 2024-09-05
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
Chugai Pharmaceutical
Phase 1 Active not recruiting
NCT06547385 2024-08-09
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT02848443 2024-07-25
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Servier
Phase 1 Completed
NCT06336707 2024-07-18
HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT04551950 2024-03-08
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
EMD Serono
Phase 1 Completed
NCT05070104 2023-09-13
CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Cornerstone Pharmaceuticals
Phase 1 Withdrawn
NCT03063762 2023-02-17
Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
Hoffmann-La Roche
Phase 1 Completed
NCT00851136 2022-12-13
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Genentech, Inc.
Phase 1 Completed